Key Takeaways
- • The Competition Commission of India (CCI) has cleared a proposed ₹3,150-crore primary capital investment by US private equity firm Advent International in Yatharth Hospital & Trauma Care Services, according to the article.
- • The investment would give Advent a 24.9 per cent stake, making it a significant minority shareholder while the founding Tyagi family remains the largest shareholder.
- • Yatharth operates nine multi-speciality hospitals with around 2,800 beds and plans to expand to more than 5,000 beds over the next three years.
- • The CCI identified Rasmalai Limited as the acquirer, indirectly controlled by investment funds managed or advised by Advent and its affiliates; the entity currently has no business activities or presence in India.
- • A detailed CCI order is still awaited.
Summary
The Competition Commission of India has cleared a proposed ₹3,150-crore investment by US private equity firm Advent International in Yatharth Hospital & Trauma Care Services, clearing the way for Advent to acquire a 24.9 per cent stake in the hospital chain. Yatharth Hospitals announced the definitive agreement on September 17, 2026, describing Advent as a leading global private equity investor.
The transaction is a primary capital infusion, meaning the funds flow directly to the company rather than to existing shareholders selling shares. Yatharth intends to use the capital to expand its hospital network. The company currently operates nine multi-speciality hospitals with around 2,800 beds and plans to grow capacity beyond 5,000 beds over the next three years. In its FY26 annual report, Yatharth said future growth will be driven by capacity creation, deeper clinical specialisation, technology adoption and expansion into underserved and high-growth catchment areas.
According to the CCI's release on Tuesday, the acquirer is Rasmalai Limited, which is indirectly controlled by investment funds managed or advised by Advent and its affiliates. The commission noted that Rasmalai Limited currently has no business activities or presence in India. Post-transaction, Advent will hold a significant minority position, while the founding Tyagi family will remain the largest shareholder. The CCI reviews transactions that meet thresholds under the Competition Act, 2002, to assess potential adverse effects on competition in relevant Indian markets. A detailed order from the commission is awaited.
The transaction is a primary capital infusion, meaning the funds flow directly to the company rather than to existing shareholders selling shares. Yatharth intends to use the capital to expand its hospital network. The company currently operates nine multi-speciality hospitals with around 2,800 beds and plans to grow capacity beyond 5,000 beds over the next three years. In its FY26 annual report, Yatharth said future growth will be driven by capacity creation, deeper clinical specialisation, technology adoption and expansion into underserved and high-growth catchment areas.
According to the CCI's release on Tuesday, the acquirer is Rasmalai Limited, which is indirectly controlled by investment funds managed or advised by Advent and its affiliates. The commission noted that Rasmalai Limited currently has no business activities or presence in India. Post-transaction, Advent will hold a significant minority position, while the founding Tyagi family will remain the largest shareholder. The CCI reviews transactions that meet thresholds under the Competition Act, 2002, to assess potential adverse effects on competition in relevant Indian markets. A detailed order from the commission is awaited.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.